3.39 USD
0 (0%)
3.39 USD
0 (0%)
Taking everything into account, SNOA scores 3 out of 10 in our fundamental rating. SNOA was compared to 190 industry peers in the Pharmaceuticals industry. SNOA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNOA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- SNOA had negative earnings in the past year.
- SNOA had a negative operating cash flow in the past year.
- In the past 5 years SNOA always reported negative net income.
- SNOA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -25.11%, SNOA is in line with its industry, outperforming 56.32% of the companies in the same industry.
- SNOA has a Return On Equity of -91.87%. This is in the lower half of the industry: SNOA underperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.11% | ||
| ROE | -91.87% | ||
| ROIC | N/A |
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SNOA has a better Gross Margin (37.68%) than 60.53% of its industry peers.
- SNOA's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for SNOA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
- SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SNOA has more shares outstanding
- Compared to 5 years ago, SNOA has less shares outstanding
- SNOA has a better debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of -18.63, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
- SNOA has a Altman-Z score of -18.63. This is amonst the worse of the industry: SNOA underperforms 81.58% of its industry peers.
- A Debt/Equity ratio of 0.01 indicates that SNOA is not too dependend on debt financing.
- SNOA's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. SNOA outperforms 56.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.63 |
ROIC/WACCN/A
WACC9.28%
2.3 Liquidity
- A Current Ratio of 2.89 indicates that SNOA has no problem at all paying its short term obligations.
- With a Current ratio value of 2.89, SNOA perfoms like the industry average, outperforming 51.58% of the companies in the same industry.
- SNOA has a Quick Ratio of 2.05. This indicates that SNOA is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.05, SNOA perfoms like the industry average, outperforming 45.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.05 |
3. Growth
3.1 Past
- SNOA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.30%, which is quite impressive.
- The Revenue has grown by 25.02% in the past year. This is a very strong growth!
- The Revenue has been decreasing by -4.44% on average over the past years.
EPS 1Y (TTM)55.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.76%
Revenue 1Y (TTM)25.02%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%56.58%
3.2 Future
- Based on estimates for the next years, SNOA will show a very strong growth in Earnings Per Share. The EPS will grow by 28.15% on average per year.
- The Revenue is expected to grow by 20.34% on average over the next years. This is a very strong growth
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3Y28.15%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3Y20.34%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year SNOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SNOA's earnings are expected to grow with 28.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.06%
EPS Next 3Y28.15%
5. Dividend
5.1 Amount
- SNOA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SONOMA PHARMACEUTICALS INC / SNOA FAQ
What is the ChartMill fundamental rating of SONOMA PHARMACEUTICALS INC (SNOA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SNOA.
Can you provide the valuation status for SONOMA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 1 / 10 to SONOMA PHARMACEUTICALS INC (SNOA). This can be considered as Overvalued.
Can you provide the profitability details for SONOMA PHARMACEUTICALS INC?
SONOMA PHARMACEUTICALS INC (SNOA) has a profitability rating of 1 / 10.
What is the financial health of SONOMA PHARMACEUTICALS INC (SNOA) stock?
The financial health rating of SONOMA PHARMACEUTICALS INC (SNOA) is 4 / 10.
Can you provide the expected EPS growth for SNOA stock?
The Earnings per Share (EPS) of SONOMA PHARMACEUTICALS INC (SNOA) is expected to decline by -96.42% in the next year.